FDA “Approves” Amarin Vascepa Off-Label Campaign; Industry Groups Urge Court Not To Take The Bait
This article was originally published in RPM Report
Executive Summary
FDA has given Amarin the go-ahead to disseminate results from the ANCHOR trial despite rejecting an explicit claim based on the study. That sounds like good news – except that it comes in the context of ongoing litigation, and amounts to an attempt to render the case irrelevant without surrendering control over off-label dissemination policies.
You may also be interested in...
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.